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Please refer to the article on page 221 of this issue
to view the questions to which these answers
refer.
CLINICAL OUTCOME
The patient was given several empirical courses of
antibiotics, with no response. Further laboratory
studies indicated: negative serology for HIV-I and
HIV-II; antinuclear antibodies <1 : 40; normal
complement levels (C3, 151mg/dL; C4, 31mg/
dL); rheumatoid factor <25 IU/mL; angiotensin-
I-converting enzyme 23U/L; thyroid-stimulating
hormone 2.62micro-IU/mL; free thyroxin (T-4)
1.2 hg/dL; and normal serum globulin electro-
phoresis.
Within 10 days of incubation, rapidly growing
mycobacteria (RGM) were isolated and identiﬁed
by standard methods [1] from skin biopsy sam-
ples. Treatment with clarithromycin (500mg twice
daily) and ciproﬂoxacin (500mg twice daily) was
commenced. DNA sequencing was performed,
and the isolate was conﬁrmed as being genetically
most closely related to Mycobacterium fortuitum.
The antimicrobial susceptibility proﬁle (MIC,
mg/L) was determined by a standard microdilu-
tion method [2]: amikacin 0.25, cefoxitine 8.0,
ciproﬂoxacin 0.06, clarithromycin 2.0, doxycycline
0.12, erythromycin 0.25, imipenem 0.25, tobramy-
cin 0.5, and trimethoprim–sulfamethoxazole 0.12.
Twelve months after oral antibiotic therapy, the
patient’s lesions resolved completely, leaving thin-
walled scars at the sites of infection.
DIAGNOSIS
Sporotrichoid lymphocutaneous infection due to
M. fortuitum complex during pregnancy.
DISCUSSION
1. Cutaneous infections due to mycobacteria other
than Mycobacterium tuberculosis are not uncom-
mon. Skin and subcutaneous involvement is the
most common early manifestation.M. fortuitum
[3], M. chelonae [4,5] and M. abscessus [6] are the
three main species of RGM associated with
human infection. In individuals with intact
immunity, cutaneous infections due to RGM
are observed after traumatic implantation, fol-
lowing reconstructive surgery [7,8], or, rarely,
as abscesses at the site of intramuscular or
subcutaneous injections [9–11]. A case of dis-
seminated M. fortuitum skin abscesses has been
described in a woman during pregnancy [12],
and as in this patient, progressive RGM infec-
tion during pregnancy probably resulted from
physiologic suppression of adaptive cellular
immune responce promoting immunologic tol-
erance during pregnancy.
2. Skin infections commonly present as localized
nodules, papules, and/or pustules [13,14]. M.
fortuitum has also been associated with inﬂam-
mation of the panniculus, which is the subcu-
taneous tissue consisting of ﬁbrocytes, ﬁbrous
trabeculae, fat cells, and blood vessels, leading
to the clinical syndrome of ‘panniculitis’ [15]. In
rare instances, despite apparently intact cellular
immunity, cutaneous infections may become
widespread [14].
3. The lymphocutaneous syndrome is character-
ized by an initial lesion that extends along the
proximal course of the area of lymph drainage,
and presents clinically as contiguous subcuta-
neous nodules and lymphangitis [16]. Several
bacterial, fungal, mycobacterial, parasitic and
viral pathogens may progress in this manner.
The sporotrichoidmanifestation is similar to the
lymphocutaneous syndrome, except that skin
and subcutaneous tissue between the involved
areas is frequently normal, and signs of lym-
phangitis are often subclinical. Pathogens
associated with a sporotrichoid presentation
include Sporothrix schenckii,Nocardia brasiliensis,
Leishmania spp., M. leprae, M. marinum, and
RGM, especially M. chelonae [4,5]. Infrequent
opportunistic fungi such as Scedosporium apios-
permum [17] and Paecilomyces spp. [18] may lead
to skin lesions resembling cutaneous sporotri-
chosis. In contrast, in the case presented, a
paradoxical spread along the distal lymphatic
distribution was seen as M. fortuitum complex
infection progressed caudally along the right
lower leg, causing three distinct lesions with
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normal interlesional skin and subcutaneous
tissue (Figure 1).
4. Clinical features of M. fortuitum infections may
be misinterpreted. In a recent report of 11
patients, two-thirds (64%) were misdiagnosed
initially, and, like the case presented, inap-
propriate empirical antimicrobial therapy was
initiated [19]. Early diagnostic biopsy and
mycobacterial cultures of tissue samples remain
the mainstay of establishing a correct diagnosis
[3]. Histopathologic features of RGM infections
can be distinct [20,21], and characteristic
dimorphic (acute and chronic) inﬂammation
or mixed suppurative reaction (granulocytes
and lymphocytes) may be present along with
tissue necrosis, which includes granulocytic
microabscesses and/or non-necrotizing granu-
lomatous reactions [19–21].
5. Infections due to non-M. tuberculosis mycobac-
teria, especially the RGM, are in general difﬁ-
cult to treat and do not respond to traditional
anti-M. tuberculosis therapy. As with other
mycobacterial infections, RGM are usually trea-
ted with multidrug regimens in order to reduce
the emergence of drug-resistant organisms.
This approach may change in future if a single,
highly active antimicrobial agent becomes
available [22]. Several antimicrobial agents
are active against the RGM [2]; a recent in vitro
antimicrobial susceptibility analysis showed
that amikacin [23], azithromycin [24], cefoxitine
[25], ciproﬂoxacin [22,25], clarithromycin
[24,25], doxycycline [25], imipenem [25] and
trimethoprim–sulfamethoxazole [25] remain
active againstM. fortuitum. Similarly, no in vitro
antimicrobial resistance was seen in the myco-
bacteria isolated from this patient. Fluoroqui-
nolones are bactericidal against most strains of
M. fortuitum, and relative bactericidal indices
for moxiﬂoxacin (1.8), ciproﬂoxacin (0.5), spar-
ﬂoxacin (0.2) and oﬂoxacin (0.2) suggest that
moxiﬂoxacin and ciproﬂoxacin, in that order,
are themost bactericidal ﬂuorinated quinolones
[26]. Aminoglycosides are bacteriostatic against
M. fortuitum, amikacin and neomycin being the
most active in this group [27]. Topical applica-
tion of neomycin-based preparations in patients
with recalcitrant cutaneous M. fortuitum infec-
tion has been recommended, but must be used
with caution until clinical validation of topical
antimicrobial therapy in this setting becomes
available. A report of successful treatment with
linezolid in a patient with progressive clarithro-
mycin-resistant RGM infection [28] provides
another possible treatment option for refractory
cases. A regimen of two active antimicrobial
agents is considered optimal for the treatment
of M. fortuitum infection [21], and in the case
presented, prolonged therapy with clarithro-
mycin and ciproﬂoxacin resulted in a complete
and durable response.
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